- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02607891
A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Zwolle, Netherlands
- SEIN - Epilepsy Institute in the Netherlands Foundation
-
-
-
-
-
Barcelona, Spain
- Hospital Universitari Vall d'Hebron
-
Madrid, Spain
- Hospital Ruber Internacional
-
Sevilla, Spain
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Göteborg, Sweden
- Sahlgrenska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Note: Participants who enroll in Sweden must be aged 18-55 years.
Key Inclusion Criteria:
Participant must be taking STP (for the STP arm) or VPA (for the VPA arm) and no more than 2 other antiepileptic drugs (AEDs) during the blinded period of the trial.
- In the VPA arm only, the participant must not be receiving STP (VPA allowed in STP arm).
- AED doses, including STP or VPA, must be stable for 4 weeks prior to screening and regimen must remain stable throughout the duration of the blinded period of the trial.
- Participant must have a documented magnetic resonance imaging/computerized tomography of the brain that ruled out a progressive neurologic condition.
- Participant must have experienced at least 1 countable uncontrolled seizure of any type (i.e., tonic-clonic, tonic, clonic, atonic, partial onset or focal: focal seizures with retained consciousness and a motor component, focal seizures with impaired consciousness, focal seizures evolving to bilateral secondary generalization) within 2 months prior to randomization.
- Intervention with vagus nerve stimulation and/or ketogenic diet must be stable for 4 weeks prior to baseline and the participant must be willing to maintain a stable regimen during the blinded period of the trial.
- Participant must abstain from alcohol during the blinded period of the trial.
Key Exclusion Criteria:
- Participant has clinically significant unstable medical conditions other than epilepsy.
- Participant has a history of symptoms related to a drop in blood pressure due to postural changes (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope).
Participant has a QT interval, corrected for heart rate with Bazett's formula (QTcB), greater than:
- 450 msec for males.
- 470 msec for females.
- 480 msec if right bundle branch block is present.
- Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month or at screening.
- Participant has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to screening or enrollment, other than epilepsy.
- Participant is currently using felbamate and has been taking it for less than 12 months prior to screening.
- Participant has consumed alcohol during the 7 days prior to enrollment and is unwilling to abstain during the blinded phase of the trail.
- Participant is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to trial entry.
- Participant has any known or suspected history of any drug abuse or addiction.
- Participant is unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex) for the duration for the study.
- Participant has consumed grapefruit or grapefruit juice 7 days prior to enrollment and is unwilling to abstain from drinking grapefruit juice within 7 days of pharmacokinetic visits.
- Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (IMP), e.g., sesame oil.
- Participant has received an IMP within the 12 weeks prior to the screening visit.
Participant has significantly impaired hepatic function at the screening or randomization visit, defined as any of the following:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 × upper limit of normal (ULN).
- ALT or AST > 3 × ULN and total bilirubin (TBL) > 2 × ULN or international normalized ratio (INR) > 1.5.
- ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: STP + GWP42003-P
Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early. STP Arm: Last patient completion October 2018 |
Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Other Names:
|
Placebo Comparator: STP + Placebo
Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early. STP Arm: Last patient completion February 2018 |
Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
|
Experimental: VPA + GWP42003-P
Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early. VPA Arm: Last patient completion February 2018 |
Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Other Names:
|
Placebo Comparator: VPA + Placebo
Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early. VPA Arm: Last patient completion January 2018 |
Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax) of STP, VPA, cannabidiol (CBD).
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The Cmax of STP, VPA and CBD is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
Time to the maximum plasma concentration (Tmax) of STP, VPA and CBD.
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The Tmax of STP, VPA and CBD is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
Area under the curve (AUC) from zero to final time of positive detection (0-t) of STP, VPA and CBD.
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The AUC(0-t) of STP, VPA and CBD is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
Area under the plasma concentration time curve over a dosing interval, where tau is the dosing interval [AUCtau].
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The AUC(tau) of STP, VPA, and CBD is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who experienced an adverse event.
Time Frame: Up to 11 weeks.
|
The number of participants who experienced an adverse event during the trial is presented.
|
Up to 11 weeks.
|
Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).
Time Frame: Up to 7 weeks.
|
The number of participants with a clinically significant change in ECG is presented.
|
Up to 7 weeks.
|
Number of participants with a clinically significant change in serum biochemistry.
Time Frame: Up to 7 weeks.
|
The number of participants with a clinically significant change in serum biochemistry is presented.
|
Up to 7 weeks.
|
Number of participants with a clinically significant change in hematology.
Time Frame: Up to 7 weeks.
|
The number of participants with a clinically significant change in hematology is presented.
|
Up to 7 weeks.
|
Number of participants with a clinically significant change in urinalysis.
Time Frame: Up to 7 weeks.
|
The number of participants with a clinically significant change in urinalysis is presented.
|
Up to 7 weeks.
|
Number of participants with a clinically significant change in vital signs.
Time Frame: Up to 7 weeks.
|
The number of participants with a clinically significant change in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) is presented.
|
Up to 7 weeks.
|
Number of participants with a clinically significant change in physical examination.
Time Frame: Up to 7 weeks.
|
The number of participants with a clinically significant change in physical examination is presented.
|
Up to 7 weeks.
|
Number of participants with a treatment-emergent suicidality flag.
Time Frame: Up to 7 weeks.
|
Suicidality was assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS).
The number of participants with a treatment-emergent flag is presented.
|
Up to 7 weeks.
|
Seizure frequency by subtype.
Time Frame: Up to 6 weeks.
|
The frequency of each subtype of seizure at baseline and end of treatment is presented.
|
Up to 6 weeks.
|
Number of participants with a treatment-emergent finding indicative of drug abuse liability.
Time Frame: Up to 7 weeks.
|
Abuse liability was assessed through monitoring of triggering adverse events of interest and study medication accountability discrepancies.
Any findings were assigned to an appropriate classification by the investigator.
The number of participants with a treatment-emergent finding indicative of drug abuse liability is presented.
|
Up to 7 weeks.
|
Cmax of 4-ene-VPA, clobazam (CLB), N-desmethylclobazam (N-CLB), levetiracetam (LEV), and topiramate (TOP).
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The Cmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
Tmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The Tmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
AUC(0-t) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The AUC(0-t) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
AUC(tau) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.
Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
The AUC(tau) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.
|
0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GWEP1447 Blinded Phase
- 2015-002939-18 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on GWP42003-P
-
Jazz PharmaceuticalsCompletedEpilepsy | Dravet SyndromeUnited States, United Kingdom
-
Jazz PharmaceuticalsRecruitingSeizure in Participants With Tuberous Sclerosis Complex | Seizure in Participants With Dravet Syndrome | Seizure in Participants With Lennox-Gastaut SyndromeUnited States
-
Jazz PharmaceuticalsWithdrawnLennox-Gastaut Syndrome
-
Jazz PharmaceuticalsCompletedEpilepsy | Dravet Syndrome | Lennox-Gastaut Syndrome
-
Jazz PharmaceuticalsTerminatedRett Syndrome | RTTUnited States, Spain, Italy, United Kingdom
-
Jazz PharmaceuticalsTerminatedSeizures Associated With EMASUnited States, Italy
-
Jazz PharmaceuticalsCompletedFatty LiverUnited Kingdom
-
Jazz PharmaceuticalsCompletedInfantile SpasmsUnited States, Poland
-
Jazz PharmaceuticalsGW PharmaceuticalsCompletedSeizures | Tuberous Sclerosis ComplexUnited States
-
Jazz PharmaceuticalsTerminatedSchizophreniaUnited States, Spain, Poland, Serbia